Cart
sales@molnova.com
Modaline sulfate
CAS No. 2856-75-9
Modaline sulfate( —— )
Catalog No. M13868 CAS No. 2856-75-9
Modaline, 2-methyl-3-piperidinopyrazine derivative, was found to inhibit monoamine oxidase (MAO) and showed therapeutic anti-depressant activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | 28 | In Stock |
|
| 50MG | 35 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameModaline sulfate
-
NoteResearch use only, not for human use.
-
Brief DescriptionModaline, 2-methyl-3-piperidinopyrazine derivative, was found to inhibit monoamine oxidase (MAO) and showed therapeutic anti-depressant activity.
-
DescriptionModaline, 2-methyl-3-piperidinopyrazine derivative, was found to inhibit monoamine oxidase (MAO) and showed therapeutic anti-depressant activity. This compound potentiated convulsions induced by tryptamine and hyperthermia induced by dopa similar to other MAO inhibitors.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetMAO
-
RecptorMAO
-
Research AreaNeurological Disease
-
Indication——
Chemical Information
-
CAS Number2856-75-9
-
Formula Weight275.33
-
Molecular FormulaC10H17N3O4S
-
Purity>98% (HPLC)
-
SolubilityWater: 10 mM
-
SMILESOS(O)(=O)=O.CC1=NC=CN=C1N1CCCCC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Tangri KK, et al. Jpn J Pharmacol. 1972 Oct;22(5):599-604.
molnova catalog
related products
-
Selegiline hydrochlo...
Selegiline hydrochloride is a selective reversible inhibitor of MAO-B (Ki = 0.091 μM) over MAO-A (Ki = 9.06 μM). Monoamine oxidase (MAO) inhibitors have utility in ameliorating a variety of neurological conditions including depression.
-
AChE/BChE/MAO-B-IN-1
AChE/BChE/MAO-B-IN-1 is a reversible, non-time-dependent inhibitor of AChE, BChE, and MAO-B that crosses the blood-brain barrier, exhibiting inhibitory effects on hAChE, hBChE, and hMAO-B with IC50s of 7.31, 0.56, and 26.1 μM, respectively.
-
Rasagiline Mesylate
Rasagiline Mesylate is a new MAO-B inhibitor for the treatment of idiopathic Parkinson's disease.
